HUMASIS (205470) Fundamentals 2026 — Revenue Analysis | SniperIQ
HUMASIS (205470) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩46.4B, trading at ₩2050.00 on the KOE. This SniperIQ fundamentals page covers HUMASIS's valuation, profitability (net margin -31.7%), revenue (₩30.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is HUMASIS's market cap?
HUMASIS (205470) has a market capitalization of approximately ₩46.4B, trading at ₩2050.00 on the KOE. Market cap moves with the live share price.
What is HUMASIS's P/E ratio?
HUMASIS's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HUMASIS?
HUMASIS runs a net profit margin of -31.7%, a gross margin of 9.5%, and an operating margin of -39.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HUMASIS generate?
HUMASIS reported revenue of ₩30.1B for fiscal year 2025, with net income of -₩15.6B and earnings per share (EPS) of -689.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HUMASIS pay a dividend?
HUMASIS does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is HUMASIS financially healthy?
HUMASIS carries a debt-to-equity ratio of 0.05x and a current ratio of 2.29x, with a market beta of -0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HUMASIS a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HUMASIS (205470) the key facts are: market cap ₩46.4B, revenue ₩30.1B, 52-week range 1958-7580. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HUMASIS's full fundamentals live
Get HUMASIS's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.